Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Novo Nordisk (NVO-2.98%) has enjoyed tremendous success with semaglutide, the proprietary drug in Ozempic and Wegovy. However, competition is picking up with multiple next-generation drugs working ...

The Danish government and the foundation behind Novo Nordisk A/S will invest €80 million ($93 million) in a Microsoft-powered ...

The move comes after Novo Nordisk’s share price fell 50% over the last 12 months, and amid growing pressure from the powerful Novo Nordisk Foundation, which controls the company’s voting majority.

Novo Nordisk (NVO-2.98%) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, ...

Novo Nordisk stock DK:NOVO.B NVO rose 2% in Copenhagen trade. But the stock is still down about 28% this year and less than half the value of its peak last June. Partner Center.

Novo Nordisk, the maker of popular drugs used for weight loss including Ozempic and Wegovy, says it is investing over $6 billion dollars to help meet the increased demand for the drugs amid ...

Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.

The Danish drugmaker, which makes Ozempic and Wegovy, has seen its stock tumble as competition in the weight-loss drug market has grown fiercer. By Rebecca Robbins Novo Nordisk will replace its ...